ArticleBMC cancer2023

Responsiveness and construct validity of EPIC-26, AQoL-6D and SF-6D following treatment in prostate cancer.

Norma B Bulamu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.